Efficacy of the HPV Vaccine in the Secondary Prevention of Cervical Dysplasia in Patients Undergoing Surgery
Bengu Mutlu Sutcuoglu11Department of Obstetrics and Gynecology, Lokman Hekim University, Ankara, Türkiye
Chronic infection with human papillomavirus (HPV) is the leading cause of cervical cancer. Patients continue to suffer from relapse or residual disease despite major advancements in diagnostic and therapeutic procedures such as colposcopy, loop electrosurgical excision procedure, and surgical conization. The most effective way to prevent cervical cancer is to avoid HPV infection. There are no definitive data on the administration of an adjuvant HPV vaccine to patients with cervical intraepithelial neoplasia who have undergone local surgical procedures. In addition, it is believed that administering an adjuvant vaccine to this patient population might very well reduce the incidence of cervical cancer. Vaccines are believed to provide protection against reinfection or reactivation for seropositive individuals whose infection has been cleared. The use of adjuvant HPV vaccine in high-risk individuals with HPV infection and HPV-related lesions is not supported by strong evidence. In this systematic review, we sought to determine the effect of HPV vaccination on the risk of HPV infection and the recurrence of pre-invasive disease associated with HPV infection after local surgical intervention for cervical disease or other HPV-associated diseases. Keywords: Cancer, cervical cancer, HPV, secondary prevention, vaccine
Cite This Article
Sutcuoglu B. Efficacy of the HPV Vaccine in the Secondary Prevention of Cervical Dysplasia in Patients Undergoing Surgery. EJMI. 2023; 7(3): 181-187
Corresponding Author: Bengu Mutlu Sutcuoglu